CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This Phase I trial studies the safety and efficacy of vaccine therapy in treating patients with previously untreated chronic lymphocytic leukemia...
Phase 1
Chicago, Illinois, United States
inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...
Phase 1, Phase 2
Chicago, Illinois, United States and 51 other locations
in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...
Phase 2
Chicago, Illinois, United States and 173 other locations
Phase 2 dose (RP2D) of SNDX-5613 in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Chicago, Illinois, United States and 47 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....
Phase 1
Chicago, Illinois, United States and 23 other locations
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in a...
Phase 1
Chicago, Illinois, United States and 14 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
Maywood, Illinois, United States and 23 other locations
complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia...
Phase 4
Park Ridge, Illinois, United States and 11 other locations
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...
Phase 1, Phase 2
Chicago, Illinois, United States and 13 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Chicago, Illinois, United States and 110 other locations
Clinical trials
Research sites
Resources
Legal